Innate Pharma 2024 Financial Calendar

Rhea-AI Summary

Innate Pharma releases its 2024 financial calendar

Positive

• Publication of 2023 financial statements on March 21, 2024
• Publication of revenue for 1Q2024 on May 14, 2024
• Annual General Shareholders Meeting on May 23, 2024
• Publication of half year financial statements on September 12, 2024
• Publication of revenue for 3Q2024 on November 13, 2024

Negative

• None.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2024 financial calendar:

March 21, 2024: Publication of 2023 financial statements

May 14, 2024: Publication of revenue for 1Q2024

May 23, 2024: Annual General Shareholders Meeting

September 12, 2024: Publication of half year financial statements

November 13, 2024: Publication of revenue for 3Q2024

All financial reports are released before market open CET.

All corporate information, such as the Company’s financial statements and corporate presentations, is available in the Investors section on https://www.innate-pharma.com.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET^® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn.

Information about Innate Pharma shares

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:
Investors
Innate Pharma  
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
 
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu

View source version on businesswire.com: https://www.businesswire.com/news/home/20231018970557/en/

Innate Pharma SA

Source: Innate Pharma SA

FAQ

What is the 2024 financial calendar of Innate Pharma?

Innate Pharma has released its 2024 financial calendar which includes the publication of financial statements and revenue updates.

When will the 2023 financial statements be published?

The 2023 financial statements will be published on March 21, 2024.

When is the Annual General Shareholders Meeting?

The Annual General Shareholders Meeting is scheduled for May 23, 2024.

When will the half year financial statements be published?

The half year financial statements will be published on September 12, 2024.

When will the revenue for 3Q2024 be published?

The revenue for 3Q2024 will be published on November 13, 2024.